http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018128408-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f4e27efe063c6cfdc546cebc6ac6b78 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-539 |
| filingDate | 2018-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df9c5972b65a1ef4cbe083e607b283be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38cb8a419e64909a07053f122e87c468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f553113fd689597087402775cce3b50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d873a0514f0357d0a8f41b9f0c2b274 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90ca6a38cde4711da2747867e8e3c504 |
| publicationDate | 2018-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018128408-A1 |
| titleOfInvention | Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, comprising baicalein as active ingredient |
| abstract | The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, the composition comprising, as an active ingredient, baicalein for controlling thymic stromal lymphopoietin (TSLP)- mediated signaling. According to the present invention, a baicalein substance extracted from Scutellaria baicalensis was confirmed to control intracellular signal transduction by TSLP, thereby inhibiting intracellular STAT5 phosphorylation and inhibiting a reaction between TSLP and TSLPR, and thus a pharmaceutical composition may be provided that is capable of effectively inhibiting the formation of inflammatory responses of allergic diseases or asthma. In addition, a pharmaceutical composition may be provided that further comprises a compound having a synergistic effect with baicalein, thereby being capable of more effectively inhibiting the formation of inflammatory responses of allergic diseases such as asthma or atopy. |
| priorityDate | 2017-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.